CZL-S092
CZL-S092 is a PLK4 inhibitor with an IC50 value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3) . CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC50 = 1.143 μM) . CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer[1].
Product Specifications
UNSPSC
12352005
Target
Polo-like Kinase (PLK)
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CN(C1=CC=CC(F)=C1)C(CSC2=CC3=C(C(/C=C/C4=CC=CN=C4)=NN3)C=C2)=O
Molecular Formula
C23H19FN4OS
Molecular Weight
418.49
References & Citations
[1]Liu N et al. Rational design of CZL-S092: A novel indazole-based PLK4 inhibitor targeting neuroblastoma through virtual screening and fragment-based drug design strategies. Eur J Med Chem. 2025 Jun 13;296:117867. doi: 10.1016
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PLK4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
